BACKGROUND

This study aimed to investigate the relationship between myonectin levels and metabolic and hormonal disorders in patients with polycystic ovary syndrome (PCOS).

METHODS

One hundred PCOS patients who sought medical advice from September 2017 to March 2019 in our hospital were selected as the PCOS group, while 100 healthy women matched for age and body mass index (BMI) with the PCOS patients were selected as the control group. General clinical information, myonectin levels, and metabolism and sex hormone-related indicators of the two groups were compared, and the correlation between myonectin, metabolism, and sex hormones was analyzed.

RESULTS

There were no significant differences in age, BMI, blood pressure, or other general clinical information between the two groups (P>0.05). Compared with the control group, the levels of myonectin, sex hormone-binding globulin (SHBG), and high-density lipoprotein cholesterol (HDL-C) in the PCOS group were significantly decreased (P<0.05), while the levels of fasting blood glucose (FBG), homeostasis model assessment of insulin resistance (HOMA-IR), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), luteinizing hormone (LH), and testosterone were significantly increased (P<0.05). Pearson correlation analysis showed that the level of myonectin was negatively correlated with BMI, FBG, HOMA-IR, TG, and testosterone but was positively correlated with SHBG and HDL-C. Multivariate linear regression analysis showed that the level of myonectin was negatively correlated with BMI, HOMA-IR, and TG but positively correlated with SHBG and HDL-C.

CONCLUSIONS

There is a correlation between the level of myonectin and multiple metabolic and hormone indices in PCOS patients indicating that myonectin may be an effective index to predict metabolic and hormone disorders in PCOS patients.